Six Dosing And Safety Considerations In The Era Of Emerging Therapies
Source: Premier Research
By Peter Larson, M.D., Senior Medical Director for Hematology-Oncology
Sponsors of emerging hematologic therapies – including gene transfer and gene editing, adoptive cellular, and antibody-drug conjugates – face a unique set of challenges in conducting early-phase, dose-finding studies.
Following are key considerations for developing early-phase trials that can more accurately define the recommended dose and identify adverse events for emerging therapies.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Premier Research
This website uses cookies to ensure you get the best experience on our website. Learn more